Filing Flows › Bioadaptives (BDPT) › Q2 2026 › vs Q1 2026
Bioadaptives (BDPT) Q2 2026 vs Q1 2026 (quarter over quarter)
Bioadaptives's revenue fell $1K (-10%) from $6K in Q1 2026 to $5K in Q2 2026.
Bioadaptives, Q2 2026: revenue $5K (+55% year over year), net earnings $150K, operating cash flow −$44K. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $5K | $6K | −$1K | -10% |
| Other income, net | $347K | $87K | $260K | +299% |
| Costs & expenses | $352K | $204K | $149K | +73% |
| Operating costs | $202K | $204K | −$2K | -0.8% |
| Net earnings | $150K | −$111K | $261K | — |
| Cost of revenue | $1K | $1K | −$1K | -47% |
| General & admin | $178K | $181K | −$3K | -2% |
| Other operating costs | $24K | $21K | $2K | +11% |
| Operating cash sources | $196K | −$25K | $221K | — |
| Depreciation | $2K | $2K | $0 | 0% |
| Cash used in operations | $44K | $85K | −$40K | -48% |
| Working capital & other | $196K | −$25K | $221K | — |
Questions
How much did Bioadaptives's revenue grow quarter over quarter in Q2 2026?
Bioadaptives's revenue fell $1K (-10%) from $6K in Q1 2026 to $5K in Q2 2026.